American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: http://www.sciepub.com/journal/ajidm Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
Go
American Journal of Infectious Diseases and Microbiology. 2013, 1(5), 96-100
DOI: 10.12691/ajidm-1-5-4
Open AccessEditorial

Markers of HIV-1 Disease Progression and Treatment Response in Highly Active Antiretroviral Therapy (HAART) Era: A Review

K V Ramana1,

1Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

Pub. Date: November 10, 2013

Cite this paper:
K V Ramana. Markers of HIV-1 Disease Progression and Treatment Response in Highly Active Antiretroviral Therapy (HAART) Era: A Review. American Journal of Infectious Diseases and Microbiology. 2013; 1(5):96-100. doi: 10.12691/ajidm-1-5-4

Abstract

After the discovery of human immunodeficiency virus 1 (HIV-1) infection more than three decades ago, there has been a significant development in the laboratory diagnosis, treatment and management of patients on highly active antiretroviral therapy (HAART). Initially HIV-1 infection was implicated to cause various cancerous conditions (Kaposi’s sarcoma), and infectious diseases (tuberculosis, other bacterial, viral, parasitic and fungal infections). Studies have demonstrated that HIV-1 infection and the disease course is complex and that many HIV infected patients do not progress to acquired immune deficiency syndrome (AIDS) even after 10-15 years (late/non progressors). Introduction of HAART has significantly reduced the morbidity and mortality in HIV-1 infected patients resulting in extended life on par with HIV non infected individuals. Late research has revealed that HIV-1-infected individuals are at greater risks of developing non infectious complications (liver disease, cardiovascular disease (CVD)) that may precipitate with the initiation of HAART. With the increased availability and affordability of HAART, the focus now is on developing effective strategies to monitor HIV -1 disease progression and treatment response.

Keywords:
human immunodeficiency virus (HIV) highly active antiretroviral therapy (HAART) disease progression treatment response

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 2

References:

[1]  Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet- Brun F., Rouzioux C., Rozenbaum W., Montagnier L., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science, 1983; 220: 868-871.
 
[2]  UNAIDS, 2006. AIDS epidemic update. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva.
 
[3]  http://2006_Epiupdate_en.pdf
 
[4]  K V Ramana. Are we close enough to get rid of AIDS: Insights in to impact of Human Immunodeficiency virus (HIV) infection post Highly Active Antiretroviral therapy (HAART) Era. International Journal of Molecular Medical Science, 2013; 3(5): 25-29.
 
[5]  Ramana K V. HIV Disease Management in the Highly Active Antiretroviral Therapy (HAART) Era. J Medical Microbiol Diagnosis 2012; 1:e101.
 
[6]  Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A.d., El-Sadr W., Thiébaut R., de Wit S., Kirk O., Fontas E., Law M.G., Phillips A., Lundgren J.D., DAD Study Group., Class of antiretroviral drugs and the risk of myocardial infarction, N. Engl J. Med., 2007; 356:1723-1735.
 
[7]  Miiro G, Nakubulwa S, Watera C, Munderi P, Floyd S, Grosskurth H. Evaluation of affordable screening markers to detect CD4+ T cell counts below 200 cells/µl among HIV-1-infected Ugandan adults. Trop Med Int Health. 2010; 15(4):396-404.
 
[8]  Azzoni L, Foulkes AS, Liu Y, Li X, Johnson M, Smith C, et al. Prioritizing CD4 Count Monitoring in Response to ART in Resource Constrained Settings: A Retrospective Application of Prediction-Based Classification. PLoS Med 2012; 9(4): e1001207
 
[9]  Ramana K V, Jagadeeswhwara chary, Sabitha V, S K Mohanty, Ratna Rao. Role of Hematological and Alternate Markers in Human Immunodeficiency Virus Disease Progression. American Medical Journal 1 (2): 84-87, 2010.
 
[10]  Ramana KV, Ratna Rao, Sabitha, Venugopal B, Rafi MD, et al. Biochemical Parameters in Human Immunodeficiency Virus Disease Progression. J Medical Microbiol Diagnosis 2012; 1:103.
 
[11]  Kandi Venkataramana. A Study of Biological Markers in HIV Disease Progression and Management in the Highly Active Antiretroviral Therapy (HAART) Era, American Journal of Bioscience and Bioengineering. 2013; 1(2): 24-37.
 
[12]  Cohen AJ, Steigbigel RT. Eosinophilia in Patients Infected with Human Immunodeficiency Virus. J Infect Dis. 1996; 174: 615-18.
 
[13]  K V Ramana, V Sabitha, Ratna Rao. A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ cell counts and Disease Progression in resource poor settings in Highly Active Antiretroviral Therapy (HAART) Era. Journal of Clinical and Diagnostic Research [serial online] 2013 July [cited: 2013 Jul 5]; 7:1332-1335.
 
[14]  Sourav Sen., Akshat Vyas, Sunil Sanghi, K Shanmuganandan, RM Gupta, Ketoki Kapila, et al. Correlation of CD4+ T cell Count with Total Lymphocyte Count, Haemoglobin and Erythrocyte Sedimentation Rate Levels in Human Immunodeficiency Virus Type-l Disease. MJAFI. 2011; 67: 15-20.
 
[15]  Kapiga SH, Mwakagile D, Spiegelman D, Msamanga GI, Hunter D, Fawzi WW. Predictors of CD4+ lymphocyte count among HIV-seropositive and HIV-seronegative pregnant women in Dar es Salaam, Tanzania. East Afr Med J. 2000 Apr; 77(4):206-11.
 
[16]  de Jong MA, Wisaksana R, Meijerink H, Indrati A, van de Ven AJ, Alisjahbana B et al. Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study. Trop Med Int Health. 2012; 17(5):581-3.
 
[17]  Lowe DM. The Erythrocyte sedimentation rate in HIV: a neglected Parameter? AIDS. 2010; 24(18):2773-5.
 
[18]  Paul Collini, Uli Schwab, Stephen Sarfo, Joseph Obeng-Baah, Betty Norman, David Chadwick, David Bibby, and George Bedu-Addo. Sustained Immunological Responses to Highly Active Antiretroviral Therapy at 36 Months in a Ghanaian HIV Cohort. Clin Infect Dis 2009; 48:988-91.
 
[19]  Crum-Cianflone NF. Immune reconstitution inflammatory syndromes: What’s new? AIDS Read 2006;16:199-206.
 
[20]  Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study. PLoS Med 2010; 7(12): e1000384.
 
[21]  Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: Clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-68.
 
[22]  Owiredu WK, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci. 2011;11(1):215.
 
[23]  Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, Ekoru K, et al. Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda. PLoS one 2011; 6(5): e19089
 
[24]  Casula M, Bosboom-Dobbelaer I, Smolders K, Otto S, Bakker M, et al. Infection with HIV-1 induces a decrease in mt-DNA. J Infect Dis 2005; 191: 1468-1471.
 
[25]  Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, et al. The HIV- 1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191: 33-46.
 
[26]  Stebbing J, Gazzard B, Douek DC Mechanisms of disease - Where does HIV live? N Engl J Med 2004; 350: 1872-1880.
 
[27]  Cooper CL HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS 2007; 2: 466-473.
 
[28]  Jason T. Blackard, Jeffrey A. Welge, Lynn E. Taylor, Kenneth H. Mayer, Robert S. Klein, David D. Celentano, Denise J. Jamieson, Lytt Gardner, and Kenneth E. Sherman. HIV Mono-infection Is Associated With FIB-4 – A Noninvasive Index of Liver Fibrosis in women. Clin Infect Dis 2011; 52 (5): 674-680.
 
[29]  Monia Mendeni, Emanuele Foca` , Daria Gotti, Nicoletta Ladisa, Gioacchino Angarano, Laura Albini, Filippo Castelnuovo, Giampiero Carosi, Eugenia Quiros-Roldan, and Carlo Torti. Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases 2011; 52(9):1164-117.
 
[30]  Ramana KV, Ratna Rao, Sabitha Abnormal Levels of γ-Glutamyl Transpeptidase (GGTP), ALT, AST in Human Immunodeficiency Virus-1(HIV-1) Infection. Biochem Physiol 2012; 1:101.
 
[31]  Stonehouse W, Kruger A, Smuts CM, Loots du T, Wentzel-Viljoen E Plasma polyunsaturated fatty acids and liver enzymes in HIV-infected subjects: the Prospective Urban and Rural Epidemiology (PURE) Study. Am J Clin Nutr 2010; 91: 729-735.
 
[32]  K V Ramana etal, Seroprevalence of blood-borne viral infections in post HAART era at a tertiary care hospital in south India: A five year trend analysis (2008-2012) and a comprehensive review. British Journal of Medicine and Medical Research 2013; 3 ( 4) : 1929-1937.
 
[33]  Mendeni M, Focà E, Gotti D, Ladisa N, Angarano G Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases 2011; 52: 1164-1173.
 
[34]  Jain MK . Mortality in Patients Coinfected with Hepatitis B Virus and HIV: Could Antiretroviral Therapy Make a Difference? Clin Infect Dis 2009; 48: 1772-1774.
 
[35]  Dr Aberg Management of Dyslipidemia and Other Cardiovascular Risk Factors in HIV-Infected Patients: Case-based Review. Top HIV Med. 2006;14(4):134-139.
 
[36]  Dr stein. Evaluating and Managing Cardiovascular Disease Risk Factors in HIV-Infected Patients. Top HIV Med. 2010; 18(5):164-168.
 
[37]  Dr Post. Predicting and Preventing Cardiovascular Disease in HIV-Infected Patients. Top Antivir Med. 2011;19(5):169-173.
 
[38]  K. V. Ramana and S. K. Mohanty Opportunistic intestinal parasites and TCD4+ cell counts in human immunodeficiency virus seropositive patients. J Med Microbiol 2009; 58: 1664-1666.
 
[39]  Vajpayee M, Mohan T. Current practices in laboratory monitoring of HIV infection. Indian J Med Res 2011; 134(6): 801-22
 
[40]  K V Ramana and Ratna rao. Human Immunodeficiency Virus disease management in Highly Active Anti-Retroviral Therapy era: a comprehensive review Ann of Trop Med Public Health 2013; 6(1): 5-9.
 
[41]  Ramana K V, Rao R, Kandi S, Singh PA, Kumar VP. Elevated activities of serum lactate dehydrogenase in human immunodeficiency virus sero-positive patients in highly active antiretroviral therapy era. J Dr NTR Univ Health Sci 2013;2:162-6.
 
[42]  Valencia ME, Laguna F, Camacho J, Castejón A, Soriano V, Adrados M, et al. Serum activity of the lactate dehydrogenase enzyme in patients with human immunodeficiency virus infection. An Med Interna 1994; 11:580-3.
 
[43]  Venkat A, Piontkowsky DM, Cooney RR, Srivastava AK, Suares GA, Heidelberger CP. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy. Ann Emerg Med 2008; 52:274-85.